Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-I&T vs Hormone Therapy in mCRPC
NCT05204927Phase 3Active, not recruiting
- Sponsor
- Curium
- Start
- Feb 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Curium. Primary endpoint: Radiographic Progression Free Survival at 34 weeks. Started Feb 2022; status: active, not recruiting.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05204927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204927.